Current partner codePEPTIDESDE
NCT04167163·Phase 4·INTERVENTIONAL

Abaloparatide Before Total Knee Arthroplasty

Status

Completed

Phase

Phase 4

Enrollment

58

Locations

1

Results

Posted

Publications

12

Study summary

What the protocol is testing.

The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.

Full detailed description

In primary unilateral total knee arthroplasty patients, The investigator will examine the effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months pre-op and continued for a total of 15 months. This will be compared to osteopenic patients receiving no therapy as well as previously published values in untreated osteoporotic patients 12 months following Total Knee Arthroplasty (TKA).

Interventions

Treatment arms and agents.

DRUG

Abaloparatide

18 month ABL treatment

Timeline

From registration to results.

  1. First posted

    Nov 18, 2019

  2. Study start

    Jan 10, 2020

  3. Primary completion

    Apr 3, 2025

  4. Study completion

    Apr 3, 2025

  5. Results posted

    Jun 5, 2026

  6. Registry updated

    Jun 5, 2026

Outcomes

What the study measures.

Primary outcomes

Change in Distal Femoral Bone Mineral Density (BMD) at the 25% Regions of Interest (ROIs)

Time frame · Baseline and approximately 18 months on study (15 months post-TKA)

Bone mineral density change at the 25% ROI of the surgical leg. Dual-energy X-ray absorptiometry (DXA) measured BMD was obtained at a point (ROI) 25% the length of the total surgical femur. Percent change at 25% ROI was calculated from baseline to 18 months.

Secondary outcomes

Change in Distal Femoral BMD at the 15% and 60% ROI

Time frame · Baseline and approximately 18 months on study (15 months post-TKA)

Bone mineral density percent change at the 15% and 60% ROI of the surgical leg

TBS Assessment by TRIP at the 15%, 25%, and 60% Femur ROIs

Time frame · 18 months on study (15 months post-TKA)

Trabecular bone score (TBS) assessment by Texture Research Investigation (Platform (TRIP) software change at the 15% and 25% femur ROIs (TBS \>1.350 is normal; TBS between 1.200 and 1.350 is indicative of partially degraded microarchitecture; and TBS \<1.200 equals degraded microarchitecture).

Knee Injury & Osteoarthritis Outcome Score (KOOS) JR

Time frame · 18 months on study (15 months post-TKA)

Patient reported knee function score. The KOOS, JR was developed from the original long version of the Knee injury and Osteoarthritis Outcome Score (KOOS) survey using Rasch analysis. The KOOS, JR contains 7 items from the original KOOS survey. Items are coded from 0 to 4, none to extreme respectively. KOOS, JR is scored by summing the raw response (range 0-28) and then converting it to an interval score (0-100). The interval score ranges from 0 to 100 where 0 represents total knee disability and 100 represents perfect knee health.

Change in Veterans RAND 12 (VR-12) Question Health Survey Score: Physical Health Component

Time frame · Baseline and approximately 18 months on study (15 months post-TKA)

12 Item Health Survey using patient's self assessment of their perspective of their health and ability to do daily functions. Scores are derived using an algorithm that is referenced to a metric centered at 50.0 where a zero score indicates the lowest level of health and 100 indicates the highest level of health.

Change in Veterans RAND 12 (VR-12) Question Health Survey Score: Mental Health Component

Time frame · Baseline and approximately 18 months on study (15 months post-TKA)

12 Item Health Survey using patient's self assessment of their perspective of their health and ability to do daily functions. Scores are derived using an algorithm that is referenced to a metric centered at 50.0 where a zero score indicates the lowest level of health and 100 indicates the highest level of health.

Forgotten Joint Survey(FJS) Score

Time frame · 18 months on study (15 months post-TKA)

FJS-12 consists of 12 questions and is scored using a 5-point response format with the raw scores transformed onto a 0- to 100-point scale. High scores indicate good outcome, that is, a high degree of forgetting the joint in everyday life (forgotten joint phenomenon).

Change in Body Composition Using Bioelectrical Impedance Analysis of Lean Mass

Time frame · Baseline and approximately 18 months on study (15 months post-TKA)

Change in total body composition using bioelectrical impedance analysis of lean mass.

Change in Body Composition Using Bioelectrical Impedance Analysis of Fat Mass.

Time frame · Baseline and approximately 18 months on study (15 months post-TKA)

Change in total body composition using bioelectrical impedance analysis of fat mass.

TKA Complications: Number of Participants Needed Revision Surgery

Time frame · 18 months on study (15 months post-TKA)

TKA complications: Number of participants needed revision surgery

TKA Complications: Number of Participants Had Fracture

Time frame · 18 months on study (15 months post-TKA)

TKA complications: Number of participants had fracture

Eligibility

Who can take part.

Minimum age
55 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria 1. Post-menopausal women and men age ge ≥ 55 years and scheduled to undergo primary TKA at the University of Wisconsin Total Joint Program. 2. Osteoporosis, i.e., BMD T-score (using female reference data) ≤ -2.5 at the lumbar spine, femoral neck OR total hip or ≤ -1.1 with Vertebral Fracture Assessment confirmed vertebral fracture or history of low-trauma nonvertebral fracture in the past 5 years OR osteopenia, BMD T-score (using female reference data) -1.1 to -2.4 at the lumbar spine, femoral neck or total hip and no prior low-trauma fracture. 3. Serum calcium (albumin-corrected), serum creatinine and Parathyroid(PTH) values all within the normal range and 25(OH)D \> 10 ng/mL. 4. Willing to supplement with daily calcium and/or vitamin D3 at protocol specified doses. 5. Able to provide written informed consent. Exclusion Criteria 1. Unevaluable distal femur BMD due to hardware or other artifacts. 2. History of bone disorders (e.g., Paget's disease) other than osteoporosis. 3. History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine. 4. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances that, in opinion of the principal investigator, would compromise study data validity. 5. History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year. 6. History of significantly impaired renal function (serum creatinine \>2.0 mg/dL. If the serum creatinine is \> 1.5 and ≤ 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be ≥ 37 mL/min. 7. History of nephrolithiasis or urolithiasis within the past five years. 8. History of cancer in prior 5 years (basal cell or squamous skin cancer is permissible). 9. History of osteosarcoma at any time. 10. Patients known to be positive for Hepatitis B, Hepatitis C, HIV-1 or HIV-2. 11. Known hypersensitivity to any of the test materials or related compounds. 12. Prior treatment with PTH- or PTHrP-derived drugs, (ABL, teriparatide or PTH (1-84)). 13. Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past three years. Patients who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment. 14. Treatment with fluoride or strontium in the past five years or prior treatment with bone-acting investigational agents at any time. 15. Treatment with calcitonin the past 6 months or denosumab in the past 18 months. 16. Treatment with anticonvulsants affecting vitamin D metabolism (phenobarbital, phenytoin, carbamazepine or primidone) or chronic heparin within the prior 6 months. 17. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) 18. Daily treatment with oral, intranasal or inhaled glucocorticoids in the prior 12 months. 19. Exposure to any investigational drug within 12 months. 20. Consumption of \> 2 alcoholic drinks per day or use of illegal drugs within 12 months of screening. 21. Not suitable for study participation due to other reasons at the investigators discretion.

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

University of Wisconsin

Madison, Wisconsin, United States

Publications

Results and literature.

PMID 26333733Maradit Kremers H, Larson DR, Crowson CS, Kremers WK, Washington RE, Steiner CA, Jiranek WA, Berry DJ. Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97. doi: 10.2106/JBJS.N.01141.PMID 17403800Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5. doi: 10.2106/JBJS.F.00222.PMID 25368498Chang CB, Kim TK, Kang YG, Seong SC, Kang SB. Prevalence of osteoporosis in female patients with advanced knee osteoarthritis undergoing total knee arthroplasty. J Korean Med Sci. 2014 Oct;29(10):1425-31. doi: 10.3346/jkms.2014.29.10.1425. Epub 2014 Oct 8.PMID 20032523Lingard EA, Mitchell SY, Francis RM, Rawlings D, Peaston R, Birrell FN, McCaskie AW. The prevalence of osteoporosis in patients with severe hip and knee osteoarthritis awaiting joint arthroplasty. Age Ageing. 2010 Mar;39(2):234-9. doi: 10.1093/ageing/afp222. Epub 2009 Dec 23.PMID 26330085Frenzel S, Vecsei V, Negrin L. Periprosthetic femoral fractures--incidence, classification problems and the proposal of a modified classification scheme. Int Orthop. 2015 Oct;39(10):1909-20. doi: 10.1007/s00264-015-2967-4. Epub 2015 Sep 2.PMID 22943223Sarmah SS, Patel S, Reading G, El-Husseiny M, Douglas S, Haddad FS. Periprosthetic fractures around total knee arthroplasty. Ann R Coll Surg Engl. 2012 Jul;94(5):302-7. doi: 10.1308/003588412X13171221592537.PMID 21566478Della Rocca GJ, Leung KS, Pape HC. Periprosthetic fractures: epidemiology and future projections. J Orthop Trauma. 2011 Jun;25 Suppl 2:S66-70. doi: 10.1097/BOT.0b013e31821b8c28.PMID 21196551Meek RM, Norwood T, Smith R, Brenkel IJ, Howie CR. The risk of peri-prosthetic fracture after primary and revision total hip and knee replacement. J Bone Joint Surg Br. 2011 Jan;93(1):96-101. doi: 10.1302/0301-620X.93B1.25087.PMID 22348954Hoffmann MF, Jones CB, Sietsema DL, Koenig SJ, Tornetta P 3rd. Outcome of periprosthetic distal femoral fractures following knee arthroplasty. Injury. 2012 Jul;43(7):1084-9. doi: 10.1016/j.injury.2012.01.025. Epub 2012 Feb 18.PMID 29066112Reeves RA, Schairer WW, Jevsevar DS. Costs and Risk Factors for Hospital Readmission After Periprosthetic Knee Fractures in the United States. J Arthroplasty. 2018 Feb;33(2):324-330.e1. doi: 10.1016/j.arth.2017.09.024. Epub 2017 Sep 23.PMID 23602235Lizaur-Utrilla A, Miralles-Munoz FA, Sanz-Reig J. Functional outcome of total knee arthroplasty after periprosthetic distal femoral fracture. J Arthroplasty. 2013 Oct;28(9):1585-8. doi: 10.1016/j.arth.2013.03.007. Epub 2013 Apr 17.PMID 28131543Ruder JA, Hart GP, Kneisl JS, Springer BD, Karunakar MA. Predictors of Functional Recovery Following Periprosthetic Distal Femur Fractures. J Arthroplasty. 2017 May;32(5):1571-1575. doi: 10.1016/j.arth.2016.12.013. Epub 2016 Dec 23.

Primary links

Continue at the source.

Related trials

More studies on Abaloparatide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.